TRIF is a critical survival factor in viral cardiomyopathy

J Immunol. 2011 Feb 15;186(4):2561-70. doi: 10.4049/jimmunol.1002029. Epub 2011 Jan 14.

Abstract

TRIF is a member of the innate immune system known to be involved in viral recognition and type I IFN activation. Because IFNs are thought to play an important role in viral myocarditis, we investigated the role of TRIF in induced myocarditis in mice. Whereas C57BL/6 (wild-type) mice showed only mild myocarditis, including normal survival postinfection with coxsackievirus group B serotype 3 (CVB3), infection of TRIF(-/-) mice led to the induction of cardiac remodeling, severe heart failure, and 100% mortality (p < 0.0001). These mice showed markedly reduced virus control in cardiac tissues and cardiomyocytes. This was accompained with dynamic cardiac cytokine activation in the heart, including a suppression of the antiviral cytokine IFN-β in the early viremic phase. TRIF(-/-) myocytes displayed a TLR4-dependent suppression of IFN-β, and pharmacological treatment of CVB3-infected TRIF(-/-) mice with murine IFN-β led to improved virus control and reduced cardiac inflammation. Additionally, this treatment within the viremic phase of myocarditis showed a significant long-term outcome indexed by reduced mortality (20 versus 100%; p < 0.001). TRIF is essential toward a cardioprotection against CVB3 infection.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adaptor Proteins, Vesicular Transport / deficiency
  • Adaptor Proteins, Vesicular Transport / genetics
  • Adaptor Proteins, Vesicular Transport / physiology*
  • Animals
  • Cardiomyopathy, Dilated / immunology*
  • Cardiomyopathy, Dilated / mortality
  • Cardiomyopathy, Dilated / therapy
  • Cells, Cultured
  • Coxsackievirus Infections / immunology*
  • Coxsackievirus Infections / mortality
  • Coxsackievirus Infections / therapy
  • Enterovirus B, Human / immunology*
  • Enterovirus B, Human / pathogenicity
  • HeLa Cells
  • Heart Failure / immunology
  • Heart Failure / mortality
  • Heart Failure / therapy
  • Humans
  • Interferon-beta / biosynthesis
  • Interferon-beta / physiology
  • Interferon-beta / therapeutic use
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Myocarditis / immunology*
  • Myocarditis / mortality
  • Myocarditis / therapy
  • Serotyping
  • Ventricular Dysfunction, Left / immunology*
  • Ventricular Dysfunction, Left / mortality
  • Ventricular Dysfunction, Left / therapy
  • Virus Replication / immunology

Substances

  • Adaptor Proteins, Vesicular Transport
  • TICAM-1 protein, mouse
  • Interferon-beta